The role of miR-26a and miR-30b in HER2+ breast cancer trastuzumab resistance and regulation of the CCNE2 gene
Published 2017 View Full Article
- Home
- Publications
- Publication Search
- Publication Details
Title
The role of miR-26a and miR-30b in HER2+ breast cancer trastuzumab resistance and regulation of the CCNE2 gene
Authors
Keywords
-
Journal
Scientific Reports
Volume 7, Issue 1, Pages -
Publisher
Springer Nature
Online
2017-01-25
DOI
10.1038/srep41309
References
Ask authors/readers for more resources
Related references
Note: Only part of the references are listed.- MicroRNAs in Breast Cancer: One More Turn in Regulation
- (2016) Pilar E. Asensio et al. CURRENT DRUG TARGETS
- Global cancer statistics, 2012
- (2015) Lindsey A. Torre et al. CA-A CANCER JOURNAL FOR CLINICIANS
- Pharmacologic Inhibition of mTOR Improves Lapatinib Sensitivity in HER2-Overexpressing Breast Cancer Cells with Primary Trastuzumab Resistance
- (2012) Sylvia S. Gayle et al. Anti-Cancer Agents in Medicinal Chemistry
- Frequent Mutational Activation of the PI3K-AKT Pathway in Trastuzumab-Resistant Breast Cancer
- (2012) S. Chandarlapaty et al. CLINICAL CANCER RESEARCH
- Trastuzumab Produces Therapeutic Actions by Upregulating miR-26a and miR-30b in Breast Cancer Cells
- (2012) Takehiro Ichikawa et al. PLoS One
- PIK3CA mutations, PTEN, and pHER2 expression and impact on outcome in HER2-positive early-stage breast cancer patients treated with adjuvant chemotherapy and trastuzumab
- (2011) J. D. Jensen et al. ANNALS OF ONCOLOGY
- miRNA-34a is associated with docetaxel resistance in human breast cancer cells
- (2011) L. Kastl et al. BREAST CANCER RESEARCH AND TREATMENT
- Molecular biology in breast cancer: Intrinsic subtypes and signaling pathways
- (2011) Pilar Eroles et al. CANCER TREATMENT REVIEWS
- MicroRNA Profile Predicts Recurrence after Resection in Patients with Hepatocellular Carcinoma within the Milan Criteria
- (2011) Fumiaki Sato et al. PLoS One
- Cyclin E amplification/overexpression is a mechanism of trastuzumab resistance in HER2+breast cancer patients
- (2011) Maurizio Scaltriti et al. PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA
- IL-24 gene transfer sensitizes melanoma cells to erlotinib through modulation of the Apaf-1 and Akt signaling pathways
- (2010) Wu-Guo Deng et al. MELANOMA RESEARCH
- Activated Phosphoinositide 3-Kinase/AKT Signaling Confers Resistance to Trastuzumab but not Lapatinib
- (2010) N. A. O'Brien et al. MOLECULAR CANCER THERAPEUTICS
- Understanding the Mechanisms Behind Trastuzumab Therapy for Human Epidermal Growth Factor Receptor 2–Positive Breast Cancer
- (2009) Neil L. Spector et al. JOURNAL OF CLINICAL ONCOLOGY
- High miR-21 expression in breast cancer associated with poor disease-free survival in early stage disease and high TGF-β1
- (2008) Biyun Qian et al. BREAST CANCER RESEARCH AND TREATMENT
- Her2-positive breast cancer: Herceptin and beyond
- (2008) Windy Dean-Colomb et al. EUROPEAN JOURNAL OF CANCER
- MicroRNA-221/222 Negatively Regulates Estrogen Receptorα and Is Associated with Tamoxifen Resistance in Breast Cancer
- (2008) Jian-Jun Zhao et al. JOURNAL OF BIOLOGICAL CHEMISTRY
- Breast Cancer Subtype Approximated by Estrogen Receptor, Progesterone Receptor, and HER-2 Is Associated With Local and Distant Recurrence After Breast-Conserving Therapy
- (2008) Paul L. Nguyen et al. JOURNAL OF CLINICAL ONCOLOGY
Discover Peeref hubs
Discuss science. Find collaborators. Network.
Join a conversationAdd your recorded webinar
Do you already have a recorded webinar? Grow your audience and get more views by easily listing your recording on Peeref.
Upload Now